AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16104966
Drug: CDUS (calculus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDUS (calculus deattachment with ultrasonic device and brushing with saline solution)
Trial: 11818641
Drug: abciximab plus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab plus low-dose heparin
Trial: 10859283
Drug: standard-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-dose heparin
Trial: 10362368
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0 to 2.5) and Aspirin (150 mg) daily
Trial: 10362368
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg) alone
Trial: 2344298
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol (700 mg/day of egg yolk cholesterol)
Trial: 7149451
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) consisting of breathing through an inspiratory resistance (IR) for 15 min twice daily for 4 weeks
Trial: 26238707
Drug: Alisporivir 600
RxNorm normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir 600 mg once daily with peginterferon-α2a and ribavirin (PR)
Trial: 26238707
Drug: Alisporivir 400
RxNorm normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir 400 mg twice daily with peginterferon-α2a and ribavirin (PR)
Trial: 24332123
Drug: DC-5ARI (discontinue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-5ARI (discontinue 5α-reductase inhibitor)
Trial: 24332123
Drug: DC-α-blocker (discontinue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-α-blocker (discontinue α-blocker)
Trial: 24332123
Drug: DC-α-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DC-α-blocker
Trial: 19028052
Drug: Cold crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold crystalloid (4 degrees C lactated Ringer's solution)
Trial: 9626838
Drug: Endothelin-1 infusion
RxNorm normalized name: nitric oxide synthase endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 infusion
Trial: 7933325
Drug: Trivalent split‐antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split‐antigen vaccine containing A/Beijing/352/89 (H3N2) and B/Bangkok/163/90 (B/Panama/45/90‐like strain)
Trial: 3261766
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of phenol (5%) in arachis oil with bulk laxative (Group 1)
Trial: 3261766
Drug: Bulk laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk laxative alone (Group 2)
Trial: 26857949
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (10 mg over 1 hour)
Trial: 18371487
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha (1.5 microg/kg every 20 days for 3 months) plus oral iron
Trial: 19361602
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral iron
Trial: 16817918
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide 10 mg t.d.s.
Trial: 16817918
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg t.d.s.
Trial: 16817918
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of hyoscine and paracetamol
Trial: 15013050
Drug: VPA 125
RxNorm normalized name: VPA 125 MG Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA 125 mg per day
Trial: 15013050
Drug: VPA 250
RxNorm normalized name: VPA 250 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA 250 mg per day
Trial: 15013050
Drug: VPA 375
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA 375 mg per day
Trial: 15013050
Drug: VPA 500
RxNorm normalized name: VPA 500 MG Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA 500 mg per day
Trial: 15013050
Drug: VPA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA (all doses)
Trial: 3012808
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg) every six hours and tobramycin (1.5 mg/kg) every eight hours
Trial: 23328235
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment for metastatic lymph nodes in Group B (13 patients)
Trial: 20801120
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of lansoprazole twice daily
Trial: 18727689
Drug: Antidepressants (AD)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (AD) + mood stabilizer (MS)
Trial: 15537676
Drug: Ketamine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (two doses of intravenous ketamine)
Trial: 12682003
Drug: Intracoronary abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary abciximab (20 mg bolus)
Trial: 12682003
Drug: Intravenous abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous abciximab (20 mg bolus)
Trial: 8728459
Drug: High-velocity, low-amplitude
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-velocity, low-amplitude cervical manipulation twice a week for 3 weeks
Trial: 8728459
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice a week for 3 weeks
Trial: 6345374
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nifedipine
Trial: 2243148
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nifedipine
Trial: 6345374
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of nifedipine (20 mg, 40 mg, 60 mg)
Trial: 31556824
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MoI) intervention with initial counseling call and up to 2 monthly follow-up calls by pharmacy students trained in MoI.
Trial: 27574437
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg once daily (qd) or twice daily (bid)
Trial: 11952200
Drug: Couples-Based Psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples-Based Psychoeducational Attention Control Treatment (PACT)
Trial: 28062087
Drug: SeB (Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeB (Sequential Boost) of 10Gy in 4 fractions or 14.88Gy in 6 fractions
Trial: 23460656
Drug: Extended cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive‐behavioral treatment with 9 additional group sessions over a 14‐week period
Trial: 23460656
Drug: Nonextended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextended treatment with 4 monthly smoking status calls
Trial: 21560485
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of salbutamol nebulized via oxygen (or compressed air)
Trial: 2665304
Drug: Transthoracal injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transthoracal injections of 0.5% solution of papain
Trial: 2665304
Drug: Active antiinflammatory
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antiinflammatory therapy and bronchosanitation measures
Trial: 28483190
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment once per week for 10 weeks
Trial: 10351466
Drug: Bi-annual, house-to-house
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-annual, house-to-house re-treatment schedule free of charge using research project staff
Trial: 10351466
Drug: Free re-treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free re-treatment service via sentinel dipping stations
Trial: 10351466
Drug: Social marketing
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social marketing approach with cost-retrieval for net re-treatment services
Trial: 7564436
Drug: External papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External papaverine application (1.5 mg/ml)
Trial: 7564436
Drug: Intraluminal papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected once
Trial: 7564436
Drug: Intraluminal papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected twice
Trial: 7564436
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (submersion in papaverine solution only)
Trial: 6113993
Drug: 2.5 gm
RxNorm normalized name: Avycaz 2.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 gm of 5% nonoxynol‐9 vaginal cream (Conceptrol) for 14 days
Trial: 6113993
Drug: 2.5 gm
RxNorm normalized name: Avycaz 2.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 gm of the cream base alone for 14 days
Trial: 31543350
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment in BRVO
Trial: 31543350
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment in CRVO
Trial: 25022125
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation combined with infusion of propofol (group A)
Trial: 20878849
Drug: Prescription sedative/hypnotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription sedative/hypnotics
Trial: 22763497
Drug: OTC analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC analgesics
Trial: 18720067
Drug: Combined surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined surgical and corticosteroid treatment (oral prednisolone for 10 days, nasal budesonide for 1 month, followed by nasal steroids for 1 year)
Trial: 18720067
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (not specified in detail)
Trial: 18720067
Drug: Combined surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined surgical and corticosteroid treatment
Trial: 15454647
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus cisplatin-based chemotherapy (C)
Trial: 9879412
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 300 mg/day suplatast tosilate alone
Trial: 9879412
Drug: Immunotherapy using
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy using standardized D. farinae alone
Trial: 9879412
Drug: Immunotherapy together
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy together with concurrent oral administration of 300 mg/day suplatast tosilate
Trial: 1357451
Drug: Clodronate 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 2.4 g daily for 24 months
Trial: 30198102
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg + tamsulosin 0.2 mg
Trial: 26651495
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Trial: 26651495
Drug: Terbinafine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 500 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Trial: 26634453
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of botulinum toxin type A
Trial: 24184035
Drug: Hydroxychloroquine niosomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine niosomal gel formulation (20mg in 20% w/v Pluronic F‐127 gel), applied once daily for 4 months
Trial: 19265345
Drug: 3‐mL conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mL conventional syringe
Trial: 19265345
Drug: 10‐mL conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mL conventional syringe
Trial: 19265345
Drug: 3‐mL RPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mL RPD
Trial: 19265345
Drug: 10‐mL RPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mL RPD
Trial: 9497117
Drug: Non-invasive electrical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive electrical stimulation, performed at home for one hour daily for a mean period of 45 days
Trial: 1411408
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg/d)
Trial: 7514874
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/d)
Trial: 12195873
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg b.i.d.
Trial: 3074464
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg trimethoprim + 800 mg sulphamethoxazole) b.i.d.
Trial: 29769203
Drug: DPP-IV inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitor alogliptin (early period up to 6 months)
Trial: 29769203
Drug: DPP-IV inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitor alogliptin (chronic period 6 months to end of follow-up)
Trial: 16155272
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (450 mg)
Trial: 10494457
Drug: CI-988 100
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-988 100 mg TID for six weeks
Trial: 1848169
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine hydrochloride (0.5 g h-1 kg-1 body weight)
Trial: 1848169
Drug: L-lysine hydrochloride
RxNorm normalized name: L-lysine hydrochloride
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-lysine hydrochloride (0.44 g h-1 kg-1 body weight)
Trial: 29604599
Drug: Garlic extract
RxNorm normalized name: Garlic Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic extract (GE) 400 mg daily for 3 months
Trial: 25015436
Drug: Valsartan/Amlodipine immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine immediate release tablets (film-coated)
Trial: 17352516
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 or 200mg once daily
Trial: 20205490
Drug: Sitagliptin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin monotherapy
Trial: 17352516
Drug: Sitagliptin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin as add-on therapy to metformin or pioglitazone
Trial: 17352516
Drug: Sitagliptin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin as add-on therapy to metformin
Trial: 15111779
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (1 mg/kg daily)
Trial: 15111779
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (7 mg/kg weekly)
Trial: 15111779
Drug: Weekly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly group
Trial: 15111779
Drug: Daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and control groups
Trial: 11157138
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (15 days i.v. followed by 21 days oral)
Trial: 9626844
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy with nitrates and atenolol or verapamil
Trial: 355024
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated patients)
Trial: 31453877
Drug: Volatile inhalational
RxNorm normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile inhalational agents (desflurane or sevoflurane)
Trial: 31547446
Drug: Twice the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice the RDA (2RDA: 1.6 g protein/kg bodyweight/day)
Trial: 31547446
Drug: Twice the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice the RDA (2RDA)
Trial: 31547446
Drug: Recommended dietary
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dietary allowance (RDA: 0.8 g protein/kg bodyweight/day)
Trial: 28544241
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 IU of RRR‐alpha‐tocopherol
Trial: 28544241
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of serum levels between treatment and control groups
Trial: 23899829
Drug: Aerobic training-estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training-estrogen therapy (AT-ET)
Trial: 23899829
Drug: Sedentary-estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedentary-estrogen therapy (SED-ET)
Trial: 21853229
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (IVTA) 4 mg
Trial: 19651674
Drug: L-arginine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (9 g/day)
Trial: 19651674
Drug: Creatine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (21 g/day)
Trial: 19651674
Drug: L-arginine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine plus creatine
Trial: 17463412
Drug: Roflumilast (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast (500 microg once daily)
Trial: 10211537
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg on day 1, then 200 mg once daily for 9 days)
Trial: 10211537
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice daily for 14 days)
Trial: 2533449
Drug: Gestrinone 2.5
RxNorm normalized name: gestrinone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 2.5 mg twice weekly
Trial: 29173736
Drug: Stimulant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant plus Parent Training (PT)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at nil μg kg(‐1) min(‐1)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.05 μg kg(‐1) min(‐1)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.10 μg kg(‐1) min(‐1)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.15 μg kg(‐1) min(‐1)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.20 μg kg(‐1) min(‐1)
Trial: 26001318
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.25 μg kg(‐1) min(‐1)
Trial: 19010636
Drug: 4 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cc fibrin glue after RILND
Trial: 14747423
Drug: Quinapril (high-tissue-penetrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (high-tissue-penetrating ACE inhibitor)